A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
S. mutilans, like other centipedes, is a predator that kills by injecting venom into its prey. Venom is injected to immobilize and break down internal tissues. Venoms of Scolopendridae, including Scolopendra mutilans, contain neurotoxins, which are suspected to be a significant fast-acting component in venoms of many centipedes. This species mainly feeds on live animals; plant materials are occasionally consumed but its consumption is considered negligible. To get hold of the prey, this centipede grabs prey with its anterior legs, and typically envenomates prey by stabbing it using its forcipules. Little quantitative ecological and behavioural work was done for centipedes. Some studies, however, have found that centipedes are highly selective and tend to strike at the head or thorax instead of the abdomen. If the bite was made on the abdomen, the centipede would usually reposition the prey and strike again on the head or thorax. Venom availability has a significant effect on predatory response. Returning to their normal attack rate after venom extraction takes more time when facing larger prey. Research on these behaviours has suggested that the reason for centipedes to reposition their prey is to enhance the speed where neurotoxins in the venom arrive at the thoracic ganglia, where it controls limb movement or the brain. This explanation was based on the position of such ganglia locating on the abdominal side (i.e.
Applied Biosystems' (now a Life Technologies brand) SOLiD technology employs sequencing by ligation. Here, a pool of all possible oligonucleotides of a fixed length are labeled according to the sequenced position. Oligonucleotides are annealed and ligated; the preferential ligation by DNA ligase for matching sequences results in a signal informative of the nucleotide at that position. Each base in the template is sequenced twice, and the resulting data are decoded according to the 2 base encoding scheme used in this method. Before sequencing, the DNA is amplified by emulsion PCR. The resulting beads, each containing single copies of the same DNA molecule, are deposited on a glass slide. The result is sequences of quantities and lengths comparable to Illumina sequencing. This sequencing by ligation method has been reported to have some issue sequencing palindromic sequences.
==== Alanine ==== The ammonia produced in neurons is fixed into α-ketoglutarate by the glutamate-dehydrogenase reaction to form glutamate, then transaminated by alanine aminotransferase into lactate-derived pyruvate to form alanine, which is exported to astrocytes. In the astrocytes, this process is then reversed, and lactate is transported in the other direction.
Sources: en.wikipedia.org
=== ColdFusion 5 === Version 5 was released in June 2001, adding enhanced query support, new reporting and charting features, user-defined functions, and improved admin tools. It was the last to be legacy coded for a specific platform, and the first release from Macromedia after their acquisition of Allaire Corporation, which had been announced January 16, 2001.
===== Rpn10 ===== Rpn10 was the first ubiquitin receptor identified on the proteasome. Rpn10 has a von Willebrand factor type A (VWA) attached to either a single Ubiquitin Interaction Motif (UIM), in yeast, or two UIMs in higher eukaryotes. The VWA domain binds between the base subcomplex and lid subcomplex of the 19S RP, while the UIM extends into a space over the AAA motor, though the UIM has not been seen in cryo-EM structures. NMR studies have shown that the UIM of Rpn10 binds mono-ubiquitin, and K48 di-ubiquitin with higher affinity. More recently, the C-terminus of Rpn10 in higher eukaryotes has been shown to bind an E3 ligase, UBE3A/E6AP (see Proteasomal Ligases).
DynaLIFE was a privately owned Canadian medical laboratory company based in Edmonton, Alberta. In May 2022, Alberta Health Services (AHS) signed a 15-year contract valued at approximately $4.8 billion with DynaLIFE to provide community laboratory services across Alberta. Province-wide service delivery began in December 2022. In August 2023, eight months after the transition, AHS terminated the agreement at the request of DynaLIFE's owners and transferred the company's Alberta operations to the publicly owned Alberta Precision Laboratories (APL). A 2025 examination by the Auditor General of Alberta found failures in governance, due diligence, risk assessment and financial analysis associated with the procurement and transition. The Auditor General attributed $77 million in non-value-added costs to the unsuccessful outsourcing initiative; AHS subsequently paid another $32 million to acquire DynaLIFE's remaining assets and liabilities.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.